Gardner Lewis Asset Management L P Vertex Pharmaceuticals Inc Transaction History

Gardner Lewis Asset Management L P

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $3.98 Million - $4.69 Million	-21,216 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $2.24 Million - $2.61 Million	-10,820 Reduced 33.77%	21,216 $4.56 Million
Q3 2020 Nov 09, 2020	SELL	$255.65 - $303.1 $44,738 - $53,042	-175 Reduced 0.54%	32,036 $8.72 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $273,507 - $358,805	-1,213 Reduced 3.63%	32,211 $9.35 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $817,458 - $1.01 Million	-4,092 Reduced 10.91%	33,424 $7.95 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $1.01 Million - $1.35 Million	-6,044 Reduced 13.88%	37,516 $8.21 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $1.6 Million - $1.8 Million	9,633 Added 28.39%	43,560 $7.38 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $95,473 - $110,414	-580 Reduced 1.68%	33,927 $6.22 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $306,175 - $364,089	1,870 Added 5.73%	34,507 $6.35 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $544,293 - $688,688	3,583 Added 12.33%	32,637 $5.41 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $25,159 - $28,911	-150 Reduced 0.51%	29,054 $5.6 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $367,214 - $428,299	2,520 Added 9.44%	29,204 $4.96 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $1.1 Million - $1.29 Million	7,287 Added 37.57%	26,684 $4.35 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $2.66 Million - $3.02 Million	19,397	19,397 $2.91 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Gardner Lewis Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Gardner Lewis Asset Management L P with notifications on news.